What’s new on the horizon for lipoprotein(a) therapies?
Prof Henry Ginsberg (Columbia University, New York, USA) overviews the latest news in novel Lp(a) therapies.
Watch video »
Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.Find out more »
Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
For expert analysis and insights